. *Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.
At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...
Our mission is to discover new ways to improve and extend people’s lives. Our vision is to be a trusted leader in changing the practice of medicine. Our mission is to discover new ways to improve and ...
Our leaders in Indonesia are experienced professionals, both in global and local pharmaceutical industry.
Report a suspected side effect related to Novartis product here.
Novartis today broke ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, designed to provide world-class scientific infrastructure and drug-discovery ...
The Novartis Board of Directors proposes a dividend payment of CHF 3.70 per share for 2025, up 5.7% from CHF 3.50 per share in the prior year, representing the 29th consecutive dividend increase since ...
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as foundation for various investigational CAR-T therapies Early data from first-in-human dose-escalation ...
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious ...
As the only IL-17A inhibitor approved for HS, Cosentyx offers a meaningful new treatment option that demonstrated reductions in inflammatory nodules and abscesses, and flares 2 HS is a chronic, ...
The preliminary results from the ongoing global phase III study STAND (NCT03814746) indicate no statistically significant difference between crizanlizumab 5mg/kg or crizanlizumab 7.5mg/kg and placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results